BCYC — BICYCLE THERAPEUTICS PLC

Nasdaq · Health Care · Pharmaceuticals · CIK 1761612 ·
Last close
$4.57
Market Cap
$230.21M
52W High
$5.76
52W Low
$4.24
ADV30
377,019
Next earnings
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 887,000 -65,589,000 -60,825,000 652,396,000 559,474,000 98,076,000
Dec 2025 47,955,000 -24,657,000 -20,154,000 717,597,000 628,110,000 107,620,000
Sep 2025 11,734,000 -65,709,000 -59,100,000 763,954,000 648,325,000 145,475,000
Jun 2025 2,920,000 -87,347,000 -78,952,000 832,184,000 721,451,000 163,269,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-229,230,000
Investing CF
$-2,459,000
Financing CF
$-144,000
CapEx
$-2,459,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.15
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-960,576,000
Inventory
Receivables
$40,917,000
ST Investments
EBIT TTM
$-217,417,000
Pretax Income TTM
$-217,620,000
Interest Exp TTM
$203,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$72,586,000
EBITDA
$-236,443,008
Free Cash Flow
$-121,572,376
Enterprise Value
$-282,240,832
Total Cash
$628,110,016
Total Debt
$16,852,000
Shares Out
50,373,281
Trailing EPS
$-3.15
Book Value
$8.79
ROE
-31.2%
ROA
-18.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 72,586,000 -247,718,000 -218,960,000 717,597,000 107,620,000 -249,675,000
Dec 2024 35,275,000 -209,153,000 -169,031,000 956,868,000 163,808,000 -164,724,000
Dec 2023 26,976,000 -189,946,000 -180,664,000 595,344,000 224,412,000 -60,628,000
Dec 2022 14,463,000 -116,653,000 -112,717,000 410,609,000 139,826,000 -86,111,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.13

Peers — same industry

TickerNameMarket CapLastDaily %
CNTN Canton Strategic Holdings, Inc. $229.66M $3.29
WHWK Whitehawk Therapeutics, Inc. $235.89M $4.77
RNA Atrium Therapeutics, Inc. $223.40M $13.06
KROS Keros Therapeutics, Inc. $222.26M $11.23
HELP CYBIN INC. $221.03M $4.43

News headlines (Yahoo Finance, 1h cache)

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
2026-05-22 15:06 · Yahoo
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
2026-05-21 21:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading
2026-05-07 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week
2026-05-01 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
2026-04-30 15:06 · Yahoo
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
2026-04-30 11:00 · Yahoo
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
2026-04-21 14:31 · Yahoo
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
2026-04-20 11:00 · Yahoo
Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus
2026-04-17 13:58 · Yahoo
European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading
2026-04-16 15:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.